Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of DiseaseChristoph Schultheiß, Mascha Binder, Lisa Paschold et al.|Immunity|2020Cited by 379
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated <i>ERBB2</i>-Positive Esophagogastric AdenocarcinomaAlexander Stein, Mascha Binder, Lisa Paschold et al.|JAMA Oncology|2022Cited by 57
Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric AdenocarcinomaPeter Thuss‐Patience, Mascha Binder, Prisca Bartels et al.|JAMA Network Open|2024Cited by 13
LBA54 Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217)Alexander Stein, Mascha Binder, Lisa Paschold et al.|Annals of Oncology|2021Cited by 10
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and ImmunotherapyJoseph Tintelnot, Mascha Binder, Lisa Paschold et al.|Cancer Immunology Research|2024Cited by 6